Adjunctive Single-Dose Liposomal Amphotericin to Prevent Cryptococcal Meningitis in People With HIV–Associated Cryptococcal Antigenemia and Low Plasma Cryptococcal Antigen Titers

David B Meya, Elizabeth Nalintya, Caleb P Skipper, Paul Kirumira, Peruth Ayebare, Rose Naluyima, Teopista Namuli, Fred Turya, Stewart Walukaga, Nicole S Engen, Kathy Huppler Hullsiek, Abduljewad Wele, Biyue Dai, David R. Boulware, Radha Rajasingham

Research output: Contribution to journalArticlepeer-review

Abstract

Background. Cryptococcal meningitis is a leading cause of AIDS-related mortality. Cryptococcal antigen (CrAg) predicts the development of meningitis. Historically, despite standard- of-care fluconazole, 25%–30% of asymptomatic CrAg-positive persons develop breakthrough meningitis or death. We evaluated whether adding single high-dose liposomal amphotericin B to standard pre-emptive fluconazole therapy could improve meningitis-free survival. Methods. Participants with human immunodeficiency virus (HIV) and asymptomatic cryptococcal antigenemia in Uganda were randomized to liposomal amphotericin B (10 mg/kg once) with fluconazole or fluconazole alone through 24 weeks. We compared 24-week, meningitis-free survival time between treatment groups. After the second interim review, the Data Safety and Monitoring Board recommended no further enrollment of participants with low plasma CrAg lateral flow assay titers (≤1:80) due to futility. Herein, we present the results of participants with low plasma CrAg titers. Results. 168 participants enrolled into the ACACIA trial had low plasma CrAg titers (≤1:80). During 24 weeks of follow-up, meningitis or death occurred in 14.5% (12/83) of participants randomized to liposomal amphotericin B with fluconazole versus 10.6% (9/85) assigned to fluconazole alone (hazard ratio, 1.42; 95% CI, .60–3.36; P = .431). Adverse events were more frequent in participants assigned to the intervention versus standard-of-care (28% vs 12%; P = .011). Conclusions. Among CrAg-positive persons with low titers (≤1:80), the addition of single-dose liposomal amphotericin B to fluconazole as pre-emptive therapy provided no additional clinical benefit. This trial provides supportive evidence that, in asymptomatic populations with low plasma CrAg titers, lumbar punctures are likely unnecessary as administration of meningitis treatment did not improve outcomes.

Original languageEnglish (US)
Pages (from-to)129-136
Number of pages8
JournalClinical Infectious Diseases
Volume80
Issue number1
DOIs
StatePublished - Jan 15 2025

Bibliographical note

Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved.

Keywords

  • cryptococcal antigen
  • cryptococcosis
  • HIV
  • meningitis

PubMed: MeSH publication types

  • Journal Article
  • Randomized Controlled Trial

Fingerprint

Dive into the research topics of 'Adjunctive Single-Dose Liposomal Amphotericin to Prevent Cryptococcal Meningitis in People With HIV–Associated Cryptococcal Antigenemia and Low Plasma Cryptococcal Antigen Titers'. Together they form a unique fingerprint.

Cite this